Open Collections

UBC Faculty Research and Publications

Profile of serogroup Y meningococcal infections in Canada : implications for vaccine selection Le Saux, Nicole; Bettinger, Julie A.; Wootton, Susan; Halperin, Scott A.; Vaudry, Wendy; Scheifele, David W.; Tsang, Raymond

Abstract

Canada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children. The result of the existing programs has been a decrease in serogroup C incidence. The second most common vaccinepreventable serogroup in Canada is serogroup Y, the incidence of which has been stable. The availability of a quadrivalent conjugate vaccine against serogroups A, C, Y and W135 focuses attention on serogroup Y disease as it becomes relatively more prominent as a cause of vaccine-preventable invasive meningococcal disease. This vaccine was licensed in November 2006 but is not routinely used except in Nunavut, New Brunswick and Prince Edward Island. To allow a better understanding of the ‘value added’ by a serogroup Y-containing vaccine, it is necessary to have a contemporary profile of Y disease in Canada. In the present paper, recent surveillance data on invasive meningococcal disease across Canada are summarized.

Item Metadata

Title
Profile of serogroup Y meningococcal infections in Canada : implications for vaccine selection
Creator
Le Saux, Nicole; Bettinger, Julie A.; Wootton, Susan; Halperin, Scott A.; Vaudry, Wendy; Scheifele, David W.; Tsang, Raymond
Date Issued
2009
Description
Canada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children. The result of the existing programs has been a decrease in serogroup C incidence. The second most common vaccinepreventable serogroup in Canada is serogroup Y, the incidence of which has been stable. The availability of a quadrivalent conjugate vaccine against serogroups A, C, Y and W135 focuses attention on serogroup Y disease as it becomes relatively more prominent as a cause of vaccine-preventable invasive meningococcal disease. This vaccine was licensed in November 2006 but is not routinely used except in Nunavut, New Brunswick and Prince Edward Island. To allow a better understanding of the ‘value added’ by a serogroup Y-containing vaccine, it is necessary to have a contemporary profile of Y disease in Canada. In the present paper, recent surveillance data on invasive meningococcal disease across Canada are summarized.
Subject
Invasive meningococcal disease; Meningococcal vaccine; Morbidity; Mortality; Neisseria meningitides; Serogroups A, C, Y, W135
Genre
Article
Type
Text
Language
eng
Date Available
2016-03-16
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial 2.5 Canada
DOI
10.14288/1.0228249
URI
http://hdl.handle.net/2429/57199
Affiliation
Infectious Diseases, Division of; Medicine, Department of; Medicine, Faculty of; Pediatrics, Department of; Non UBC
Citation
Le Saux, N., Bettinger, J. A., Wootton, S., Halperin, S. A., Vaudry, W., Scheifele, D. W., & Tsang, R. (2009). Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. The Canadian Journal of Infectious Diseases & Medical Microbiology, 20(4), e134.
Peer Review Status
Reviewed
Scholarly Level
Faculty
Rights URI
http://creativecommons.org/licenses/by-nc/2.5/ca/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial 2.5 Canada